ClinicalTrials.gg
CompletedNCT00929240Updated Mar 3, 2015Results posted

A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

A Phase 3 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 63 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
47th of 227
287 · median 54
Started
2009
with 11 others
Phase 3
45 of 233
5 open now
Registered
106th of 233
by date
Lead sponsor
12 of 233
Hoffmann-La Roche

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 47th largest by enrollment of the 227 interventional ones that give a count, is one of 12 that started in 2009, is one of 45 in phase 3, and was the 106th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel + Avastin. Eligible patients will receive up to 6 x 3 week cycles of treatment with Avastin (15 mg/mg IV on Day 1 of each cycle) + docetaxel (75-100 mg/m2 IV on Day 1 of each cycle). Those patients who do not progress will be randomized to 3 week cycles of either a) Avastin (15 mg/kg IV on Day 1 of each cycle) + Xeloda (1000 mg/m2 po bid on Days 1-14 of each cycle) or b) Avastin alone. Study treatment will continue until disease progression, unacceptable toxicity, patient request for withdrawal or end of study, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • -negative breast cancer
  • candidates for taxane-based chemotherapy;
  • performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • previous chemotherapy for breast cancer;
  • prior /neo-adjuvant chemotherapy within 6 months prior to study;
  • prior radiotherapy for treatment of metastatic disease;
  • chronic daily treatment with aspirin (325 mg/day) or clopidogrel(>75mg/day).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
287 participants (actual)

Study arms

  • Active comparator
    Avastin (bevacizumab)

    Drug: bevacizumab [Avastin]

  • Experimental
    Avastin (bevacizumab) + Xeloda (capecitabine)

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)

    Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions.

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

  2. Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)

    PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

Secondary outcomes

  1. Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)

    Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Progressive disease (PD) was defined as 20% increase in the sum of the longest diameter of target lesions and SD was defined as small changes that do not meet above criteria. Pearson-Clopper one-sample method was used for Confidence intervals (CIs).

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

  2. Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)

    CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

  3. Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

  4. Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)

    Duration of Overall Survival (OS) was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. Kaplan Meier estimation was used to determine OS.

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

  5. Percentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)

    Probability of being alive after 1 and 2 years on treatment with 95% CIs was calculated using Kaplan Meier approach with LOGLOG transformation.

    Time frame: Years 1 and 2

  6. Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)

    PD was defined per RECIST 1.0 as 20% increase in the sum of the longest diameter of target lesions.

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013

  7. Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)

    Time to Progression was defined as the time from randomization to the first documented disease progression (using investigator assessments of disease progression by RECIST 1.0). PD was defined as 20% increase in the sum of the longest diameter of target lesions.

    Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013

  8. Quality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)

    The EORTC QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase.

    Time frame: Baseline, Randomization and Cycles 3, 6, 9 and 12

  9. Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)

    Objective Response was determined by the investigator using RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Pearson-Clopper one-sample method was used for CI.

    Time frame: Screening and at the end of every third cycle until randomization for an average of 18 weeks

  10. Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)

    CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.

    Time frame: Screening and at the end of every third cycle until randomization for an average of 18 weeks

07

Results

Posted Mar 3, 2015

Participant flow

Initial Treatment Phase
Participant flow — Initial Treatment Phase
MilestoneInitial Treatment Phase: Bevacizumab Plus (+) DocetaxelMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Started28400
Completed18500
Not completed9900
Withdrew: Adverse event3100
Withdrew: Disease progression4100
Withdrew: Withdrawal by subject1300
Withdrew: Protocol violation500
Withdrew: Death200
Withdrew: Health authority/study termination300
Withdrew: Physician decision400
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneInitial Treatment Phase: Bevacizumab Plus (+) DocetaxelMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Started09491
Completed000
Not completed09491
Withdrew: Disease progression07360
Withdrew: Adverse event0912
Withdrew: Withdrawal by subject026
Withdrew: Protocol violation010
Withdrew: Health authority/study termination012
Withdrew: Physician decision021
Withdrew: Change of treatment040
Withdrew: Treatment ongoing at study closure0010
Withdrew: Participant not treated020

Outcome measures

PrimaryPercentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)

Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions.

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)
percentage of participantsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)88.375.8
PrimaryProgression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)

PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Reported as:
Median · months
Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)
monthsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)4.3 (3.9 to 6.8)11.9 (9.8 to 15.4)
Statistical analysis
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Log Rank · p = <0.0001 (Stratified by interactive voice/Web response system (IVRS), estrogen receptor (ER) status, visceral metastasis (yes/no), response to initial phase, and lactate dehydrogenase (LDH) level.) · Hazard ratio (hr): 0.383 · 95% CI 0.266 to 0.551Stratified by IVRS, ER status, visceral metastasis (yes/no), response to initial phase, and LDH level.
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.429 · 95% CI 0.309 to 0.597Unstratified analysis
SecondaryPercentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)

Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Progressive disease (PD) was defined as 20% increase in the sum of the longest diameter of target lesions and SD was defined as small changes that do not meet above criteria. Pearson-Clopper one-sample method was used for Confidence intervals (CIs).

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)
percentage of participantsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)76.6 (66.7 to 84.7)85.7 (76.8 to 92.2)
Statistical analysis
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Chi-squared · p = 0.113 · Mean difference (final values): 9.1 · 95% CI -2.1 to 20.3CIs with Hauck-Anderson adjustment for difference in rates of bevacizumab + capecitabine arm to bevacizumab alone arm.
SecondaryPercentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)

CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)
percentage of participantsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)97.9 (92.5 to 99.7)98.9 (94.0 to 100.0)
Statistical analysis
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Chi-squared · p = 0.580 · Mean difference (final values): 1.0 · 95% CI -2.6 to 4.6CIs with Hauck-Anderson adjustment for difference in rates of Bevacizumab+Capecitabine group to Bevacizumab only group.
SecondaryPercentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)
Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)
percentage of participantsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)56.436.3
SecondaryOverall Survival (Maintenance Phase Data Cutoff October 4, 2013)

Duration of Overall Survival (OS) was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. Kaplan Meier estimation was used to determine OS.

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Reported as:
Median · months
Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)
monthsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)23.7 (18.5 to 31.7)39.0 (32.3 to NA)
Statistical analysis
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Log Rank · p = <0.0003 (Stratified by IVRS, ER status, visceral metastasis (yes/no), response to initial phase, and LDH level.) · Hazard ratio (hr): 0.425 · 95% CI 0.263 to 0.685
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Log Rank · p = 0.002 (Unstratified analysis) · Hazard ratio (hr): 0.516 · 95% CI 0.334 to 0.798
SecondaryPercentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)

Probability of being alive after 1 and 2 years on treatment with 95% CIs was calculated using Kaplan Meier approach with LOGLOG transformation.

Time frame:
Years 1 and 2
Reported as:
Number · percentage of participants
Percentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)
percentage of participantsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
1 Year71.6 (61.1 to 79.7)90.4 (81.8 to 95.1)
2 Years49.4 (38.5 to 59.3)69.0 (57.6 to 77.9)
SecondaryPercentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)

PD was defined per RECIST 1.0 as 20% increase in the sum of the longest diameter of target lesions.

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013
Reported as:
Number · percentage of participants
Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)
percentage of participantsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)88.374.7
SecondaryTime To Progression (Maintenance Phase Data Cutoff October 4, 2013)

Time to Progression was defined as the time from randomization to the first documented disease progression (using investigator assessments of disease progression by RECIST 1.0). PD was defined as 20% increase in the sum of the longest diameter of target lesions.

Time frame:
Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013
Reported as:
Median · months
Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)
monthsMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)4.3 (3.9 to 6.8)11.9 (9.8 to 15.4)
Statistical analysis
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Log Rank · p = <0.0001 (Stratified by IVRS, ER status, visceral metastasis (yes/no), response to initial phase, and LDH level.) · Hazard ratio (hr): 0.383 · 95% CI 0.266 to 0.551Stratification variables are randomisation stratification parameters as of IVRS: ER status, Visceral metastasis (yes/no), Response to initial phase, LDH concentration level.
  • Maintenance Phase: Bevacizumab vs Maintenance Phase: Bevacizumab + Capecitabine · Log Rank · p = <0.0001 (Unstratified analysis) · Hazard ratio (hr): 0.425 · 95% CI 0.305 to 0.591Hazard ratio was determined using the cox regression model.
SecondaryQuality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)

The EORTC QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase.

Time frame:
Baseline, Randomization and Cycles 3, 6, 9 and 12
Reported as:
Mean · units on a scale
Quality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)
units on a scaleMaintenance Phase: BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Randomization (n= 83, 86)-3.51 (-9.63 to 2.60)-4.46 (-9.40 to 0.48)
Cycle 3 (n= 44, 52)0.76 (-6.65 to 8.17)-3.21 (-9.99 to 3.58)
Cycle 6 (n= 26, 54)4.17 (-6.49 to 14.82)-5.40 (-11.67 to 0.87)
Cycle 9 (n= 18, 37)8.80 (-4.57 to 22.17)-1.80 (-8.92 to 5.32)
Cycle 12 (n= 12, 31)0.69 (-17.99 to 19.37)0.00 (-8.24 to 8.24)
SecondaryPercentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)

Objective Response was determined by the investigator using RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Pearson-Clopper one-sample method was used for CI.

Time frame:
Screening and at the end of every third cycle until randomization for an average of 18 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)
percentage of participantsInitial Treatment Phase: Bevacizumab + Docetaxel
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)8.8 (4.1 to 16.1)
SecondaryPercentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)

CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.

Time frame:
Screening and at the end of every third cycle until randomization for an average of 18 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)
percentage of participantsInitial Treatment Phase: Bevacizumab + Docetaxel
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)56.9 (46.7 to 66.6)

Adverse events

Collected over Adverse Events (AEs) were recorded from the date of randomization until the end of study at the cutoff date of October 4, 2013.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Treatment Phase:Bevacizumab + Docetaxel—78/284 (27.5%)40/284 (14.1%)
Maintenance Phase:Bevacizumab—7/92 (7.6%)4/92 (4.3%)
Maintenance Phase: Bevacizumab + Capecitabine—10/91 (11%)32/91 (35.2%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventInitial Treatment Phase:Bevacizumab + DocetaxelMaintenance Phase:BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Febrile neutropeniaBlood and lymphatic system disorders28/2840/920/91
NeutropeniaBlood and lymphatic system disorders17/2840/920/91
Myocardial infarctionCardiac disorders0/2840/922/91
GastroenteritisInfections and infestations2/2842/920/91
PneumoniaInfections and infestations5/2841/920/91
Mucosal inflammationGeneral disorders4/2840/920/91
ThrombocytopeniaBlood and lymphatic system disorders0/2840/921/91
Respiratory tract infectionInfections and infestations1/2840/921/91
InfectionInfections and infestations0/2840/921/91
DysphagiaGastrointestinal disorders0/2840/921/91
Most frequent other events
Most frequent other events
EventInitial Treatment Phase:Bevacizumab + DocetaxelMaintenance Phase:BevacizumabMaintenance Phase: Bevacizumab + Capecitabine
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders6/2840/9229/91
NeutropeniaBlood and lymphatic system disorders29/2841/922/91
HypertensionVascular disorders5/2843/927/91

Baseline characteristics

Initial Phase Intent-to-Treat (ITT) population: all participants who were enrolled.

Age, Continuous
Age, Continuous(years)Intial Treatment Phase: Bevacizumab + Docetaxel
Mean52.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Intial Treatment Phase: Bevacizumab + Docetaxel
Female287
Male0
08

Study locations

63 sites
  • Fortaleza, CE 60336-550, Brazil
  • Belo Horizonte, MG 30190-130, Brazil
  • Rio de Janeiro, RJ 20560-120, Brazil
  • Ijui, RS 98700-000, Brazil
  • Porto Alegre, RS 90035-003, Brazil
  • Jau, SP 17210-080, Brazil
  • Santo Andre, SP 09060-650, Brazil
  • Sao Paulo, SP 01246-000, Brazil
  • Sao Paulo, SP 08270-070, Brazil
  • Beijing, 100021, China
  • Beijing, 100071, China
  • Beijing, 100853, China
  • Hangzhou, 310009, China
  • Hangzhou, 310022, China
  • Shanghai, 200032, China
  • Alexandria, 11737, Egypt
  • Cairo, 11796, Egypt
  • Amiens, 80090, France
  • Angers, 49933, France
  • Besancon, 25030, France
  • Bobigny, 93009, France
  • Dijon, 21079, France
  • Hyeres, 83400, France
  • Le Coudray, 28630, France
  • Lille, 59000, France
  • Paris, 75231, France
  • Paris, 75970, France
  • Perigueux, 24000, France
  • Rodez, 12027, France
  • St Priest En Jarez, 42271, France
  • Strasbourg, 67010, France
  • Hong Kong, 852, Hong Kong
  • Hong Kong, Hong Kong
  • Bangalore, 560027, India
  • Hyderabad, 500034, India
  • Mumbai, 400012, India
  • Mumbai, 400020, India
  • New Delhi, 110 060, India
  • New Delhi, 110085, India
  • Napoli, Campania 80131, Italy
  • Trieste, Friuli-Venezia Giulia 34100, Italy
  • Genova, Liguria 16132, Italy
  • Saronno, Lombardia 21047, Italy
  • Brindisi, Puglia 72100, Italy
  • Antella (FI), Toscana 50011, Italy
  • Bydgoszcz, 85-796, Poland
  • Wroclaw, 53-413, Poland
  • Dammam, 31444, Saudi Arabia
  • Jeddah, 21497, Saudi Arabia
  • Jeddah, 21589, Saudi Arabia
  • Alcoy, Alicante 03804, Spain
  • Sabadell, Barcelona, Barcelona 08208, Spain
  • Alcazar de S. Juan, Ciudad Real 13600, Spain
  • Barakaldo, Vizcaya 48903, Spain
  • Jaen, 23007, Spain
  • Malaga, 29010, Spain
  • Toledo, 45004, Spain
  • Valencia, 46026, Spain
  • Ankara, 06500, Turkey
  • Ankara, 06800, Turkey
  • Antalya, 07070, Turkey
  • Istanbul, 34000, Turkey
  • Sıhhiye, ANKARA, 06100, Turkey
09

References and documents

Publications

  • Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1351-60. doi: 10.1016/S1470-2045(14)70444-9. Epub 2014 Sep 28. PubMed 25273343 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2009
First posted
Jun 26, 2009
Start
Jul 2009
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Mar 3, 2015
Last update
Mar 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00929240
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 26, 2009
Start date
Jul 2009
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Mar 3, 2015
Last update
Mar 3, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion